Hemophilia A
Mostrando 1-12 de 165 artigos, teses e dissertações.
-
1. Causes of death and mortality trends related to hemophilia in Brazil, 1999 to 2016
ABSTRACT Introduction Multiple cause of death methodology enhances mortality studies beyond the traditional underlying cause of death approach. Aim: This study aims to describe causes of death and mortality issues related to haemophilia with the use of multiple-cause-of-death methodology. Methods: Annual male haemophilia mortality data was extracted from
Hematol., Transfus. Cell Ther.. Publicado em: 2021-06
-
2. Yttrium-90 radiosynovectomy in knees and ankles (25 joints in 22 hemophilic patients). Short-term results
ABSTRACT Introduction: The radiosynovectomy (RS) is one treatment option for recurrent hemarthrosis in patients with hemophilia (PWH). A prospective cohort study was designed to evaluate the effects of the RS on the synovial membrane volume in the ankles and knees of PWH and patient characteristics related to the RS outcome. Methods: In a one-year follow-u
Hematol., Transfus. Cell Ther.. Publicado em: 2021-03
-
3. Erratum on "Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation"
ABSTRACT Introduction: von Willebrand's disease (VWD) is the most common inherited bleeding disorder. The 1-desamino-8-d-arginine vasopressin (DDAVP) is the treatment of choice for most responsive patients with VWD. The aim of this study was to evaluate DDAVP use in the management of VWD. Method: We implemented a survey targeting medical doctors involved i
Hematol., Transfus. Cell Ther.. Publicado em: 2021-03
-
4. Desmopressin acetate use in von Willebrand's disease: a survey on current practices in Brazil
ABSTRACT Introduction: von Willebrand's disease (VWD) is the most common inherited bleeding disorder. The 1-desamino-8-d-arginine vasopressin (DDAVP) is the treatment of choice for most responsive patients with VWD. The aim of this study was to evaluate DDAVP use in the management of VWD. Method: We implemented a survey targeting medical doctors involved i
Hematol., Transfus. Cell Ther.. Publicado em: 2021-03
-
5. COVID-19 and acute mesenteric ischemia: A review of literature
ABSTRACT Introduction: von Willebrand's disease (VWD) is the most common inherited bleeding disorder. The 1-desamino-8-d-arginine vasopressin (DDAVP) is the treatment of choice for most responsive patients with VWD. The aim of this study was to evaluate DDAVP use in the management of VWD. Method: We implemented a survey targeting medical doctors involved i
Hematol., Transfus. Cell Ther.. Publicado em: 2021-03
-
6. Second COVID-19 infection in a patient with multiple myeloma in Brazil - reinfection or reactivation?
ABSTRACT Introduction: von Willebrand's disease (VWD) is the most common inherited bleeding disorder. The 1-desamino-8-d-arginine vasopressin (DDAVP) is the treatment of choice for most responsive patients with VWD. The aim of this study was to evaluate DDAVP use in the management of VWD. Method: We implemented a survey targeting medical doctors involved i
Hematol., Transfus. Cell Ther.. Publicado em: 2021-03
-
7. Outcome of SARS-CoV-2 and immune thrombocytopenia in a pediatric patient
ABSTRACT Introduction: von Willebrand's disease (VWD) is the most common inherited bleeding disorder. The 1-desamino-8-d-arginine vasopressin (DDAVP) is the treatment of choice for most responsive patients with VWD. The aim of this study was to evaluate DDAVP use in the management of VWD. Method: We implemented a survey targeting medical doctors involved i
Hematol., Transfus. Cell Ther.. Publicado em: 2021-03
-
8. The existing scenario of haemophilia care in Canada and China - A review
ABSTRACT Hemophilia is an X-linked recessive genetic disorder which affects approximately 400,000 people globally. Differing healthcare reimbursement systems, budgetary constraints and geographical and cultural factors make it difficult for any country to fully deliver ideal care. Although developed countries have sufficient treatment products available, the
Hematol., Transfus. Cell Ther.. Publicado em: 2020-10
-
9. Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires
ABSTRACT Introduction: Hemophilia is a coagulopathy caused by a deficiency in coagulation factors VIII (hemophilia A) or IX (hemophilia B). It is a chronic disease and, hence, impairs the quality of life (Qol) of the patients. This study aimed to evaluate the Qol of patients with hemophilia using the WHOQOL-bref and the Haemo-A-Qol instruments, its relation
Hematol., Transfus. Cell Ther.. Publicado em: 25/11/2019
-
10. Prevalence of symptoms in hemophilia carriers in comparison with the general population: a systematic review
ABSTRACT Introduction: Hemophilia is well known in males, but poorly recognized in hemophilia carriers, who may have a hemorrhagic tendency, and the symptoms may be frequent and severe. Few studies have been done evidencing this bleeding in female carriers of the hemophilia gene. Objectives: To verify the prevalence of hemorrhagic symptoms in HC, compared
Hematol., Transfus. Cell Ther.. Publicado em: 25/11/2019
-
11. Standardization and evaluation of the performance of the thrombin generation test under hypo- and hypercoagulability conditions
ABSTRACT Background: In order to standardize a thrombin generation() protocol, we analyzed the analytical variables and sensitivity of this test to hypo/hypercoagulability states. Methods: The effect of the tissue factor concentration and the intra- and interassay precision were analyzed. To evaluate the hypercoagulability status, the plasma of women under
Hematol., Transfus. Cell Ther.. Publicado em: 10/10/2019
-
12. Systematic molecular analysis of hemophilia A patients from Colombia
Abstract Hemophilia A (HA) is an X-linked recessive disorder and the second most common coagulation disorder with an incidence of 1 in 5,000 live born males. Worldwide, there are 178,500 affected individuals, 60% with the severe form of the disease. Intron 22 and 1 inversions (Inv22 and Inv1) are the most frequent molecular alterations found in severe HA pat
Genet. Mol. Biol.. Publicado em: 14/11/2018